Please use this identifier to cite or link to this item:
Title: Biliary tract cancers: SEOM clinical guidelines.
Issue Date: Dec-2015
Citation: Clin Transl Oncol.2015 Dec;(17)12:982-7
Abstract: Biliary tract cancer (BTC) is an uncommon and highly fatal malignancy. It is composed of three main different entities; Gall bladder carcinoma (GBC), intrahepatic cholangiocarcinoma (iCC) and extrahepatic cholangiocarcinoma (eCC) sharing different genetic, risk factors and clinical presentation. Multidetector-row computed tomography (MDCT) and magnetic resonance cholangio-pancreatography (MRCP) are the more important diagnostic techniques. Surgery is the only potentially curative therapy but disease recurrence is frequent. Treatment with chemotherapy, radiotherapy or both has not demonstrated survival benefit in the adjuvant setting. Cisplatin plus gemcitabine constitutes the gold standard in metastatic disease. New ongoing studies mainly in the adjuvant and neoadjuvant setting along with molecular research will hopefully help to improve survival and quality of life of this disease.
PMID: 26607930
Rights: openAccess
Appears in Collections:Hospitales > H. U. Infanta Sofía > Artículos

Files in This Item:
File Description SizeFormat 
PMC4689747.pdf399.87 kBAdobe PDFThumbnail

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.